NCT02958202View on ClinicalTrials.gov

Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

BMN 044 IV 6 mg/kg

DRUG

BMN 044 IV 9 mg/kg

DRUG

BMN 044 SC 6 mg/kg

Trial Locations (5)

Unknown

Universitair Ziekenhuis Leuven, Leuven

S.Anna Hospital, Ferrara

Policlinico Univsersitario Agostino Gemelli, Rome

Drottning Silvias Barn- ochungdomssjukhus, Gothenburg

2333 ZA

Leiden University Medical Center, Leiden

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY